Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modeling zidovudine therapy: a cost-effectiveness analysis.

A D Paltiel1, E H Kaplan

  • 1Department of Operations Research, Yale University, New Haven, Connecticut.

Journal of Acquired Immune Deficiency Syndromes
|January 1, 1991
PubMed
Summary

Zidovudine (ZDV) therapy for HIV/AIDS extends patient life without increasing virus spread or costs. This HIV treatment is cost-effective, especially with prevention efforts.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis.

Osteoarthritis and cartilage·2022
Same author

Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement.

Osteoarthritis and cartilage·2018
Same author

Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation.

Osteoarthritis and cartilage·2018
Same author

Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.

Osteoarthritis and cartilage·2016
Same author

Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.

Osteoarthritis and cartilage·2015
Same author

Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?

Osteoarthritis and cartilage·2013

Area of Science:

  • Public Health
  • Epidemiology
  • Health Economics

Background:

  • Zidovudine (ZDV) was the first FDA-approved therapy for HIV/AIDS.
  • Concerns exist regarding ZDV's impact on HIV transmission and societal costs.
  • Policymakers face a dilemma balancing ZDV benefits against potential risks.

Purpose of the Study:

  • To model the impact of ZDV therapy on HIV transmission and costs in a specific population.
  • To evaluate the cost-effectiveness of ZDV therapy.
  • To address fears of increased AIDS incidence and costs due to ZDV.

Main Methods:

  • Development of a simple mathematical model.
  • Simulation of ZDV therapy within a population of sexually active gay men.
  • Analysis of HIV transmission dynamics and associated costs.

Related Experiment Videos

Main Results:

  • No evidence found to support fears of increased AIDS incidence or costs from widespread ZDV distribution.
  • ZDV therapy demonstrated cost-effectiveness.
  • Cost-effectiveness is enhanced with modest promotion of behavior change and prevention.

Conclusions:

  • Widespread ZDV distribution is unlikely to increase AIDS incidence or costs among gay men.
  • ZDV therapy is a cost-effective intervention for HIV/AIDS.
  • Combining ZDV with prevention strategies further improves its cost-effectiveness.